Document Detail

DNA vaccination for cancer treatment.
MedLine Citation:
PMID:  7614247     Owner:  NLM     Status:  MEDLINE    
The recent finding that inoculation with plasmids encoding a variety of proteins leads to T cell and antibody responses in vivo against these proteins provides a novel means of active specific immunisation by plasmid vaccination. The demonstration that both major histocompatibility complex (MHC) Class I- and Class II-mediated interactions can be elicited may make this approach suitable for development of tumour vaccines. Plasmids may prove to be an efficient way to build 'subunit' and multi-subunit vaccines based on the genetic changes that occur in carcinogenesis. Expression of DNA encoding fragments of tumour-specific proteins as neo-antigens or surrogate antigens in a novel context may be a means of breaking immunological tolerance and lead to the generation of tumour-specific immune responses.
R A Spooner; M P Deonarain; A A Epenetos
Related Documents :
24508037 - Safety and serological response to a matrix gene-deleted rabies virus-based vaccine vec...
18043737 - A novel multi-antigen virally vectored vaccine against mycobacterium avium subspecies p...
12384547 - Immunogenicity of a plasmid dna vaccine encoding chimeric idiotype in patients with b-c...
12757627 - The combination of plasmid interleukin-12 with a single dna vaccine is more effective t...
3921367 - Pcbs, pcqs and pcdfs in tissues of yusho and yu-cheng patients.
23664997 - Different kinetics of circulating antibody-secreting cell responses after primary and b...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Gene therapy     Volume:  2     ISSN:  0969-7128     ISO Abbreviation:  Gene Ther.     Publication Date:  1995 May 
Date Detail:
Created Date:  1995-08-24     Completed Date:  1995-08-24     Revised Date:  2006-05-01    
Medline Journal Info:
Nlm Unique ID:  9421525     Medline TA:  Gene Ther     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  173-80     Citation Subset:  IM    
Department of Clinical Oncology, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
DNA / therapeutic use*
Gene Therapy / methods*
Histocompatibility Antigens Class I / immunology
Histocompatibility Antigens Class II / immunology
Immunotherapy / methods*
Neoplasms / therapy*
Plasmids / therapeutic use
Reg. No./Substance:
0/Histocompatibility Antigens Class I; 0/Histocompatibility Antigens Class II; 9007-49-2/DNA

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Higher plasma IGF-1 levels are associated with increased delta sleep in healthy older men.
Next Document:  Inhibition of HIV-1 by a double transdominant fusion gene.